Citigroup Maintains Buy on Attovia Therapeutics, Raises Price Target to $34

Benzinga · 2d ago
Citigroup analyst Yigal Nochomovitz maintains Attovia Therapeutics (NASDAQ:ATTO) with a Buy and raises the price target from $30 to $34.